外周插入中心導管市場 - 按產品、管腔、應用、最終用途和預測，2024 年 - 2032 年

由於癌症、糖尿病和心血管疾病等慢性疾病盛行率上升，需要長時間服用藥物和液體，周邊插入中心導管市場規模預計在 2024 年至 2032 年期間複合年成長率為 9.6%。根據世界衛生組織的數據，2022 年將通報約 2,000 萬新發癌症病例，導致 970 萬人死亡。周邊插入中心靜脈導管 (PICC) 是傳統中心靜脈導管的可靠且侵入性較小的替代方案，可為患者提供數週至數月的延長血管通路。這使得它們在醫院和門診中得到廣泛採用，促進化療、腸外營養和抗生素等療法的實施。

用於精確放置的抗菌塗層和不透射線材料以及整合沖洗系統等創新正在改善感染控制、成像下的可視性以及整體導管管理。微創手術和門診護理模式的轉變也支持了 PICC 的採用，因為與傳統中心靜脈導管相比，它們可降低併發症發生率並縮短住院時間。

周邊插入中心導管產業分為產品、管腔、應用、最終用途和區域。

從產品來看，傳統人保財險業務的市場規模預計將在2024 年至2032 年期間產生可觀的收入，因為其在安全性、可靠性和醫療保健提供者之間的熟悉度方面有著良好的記錄。傳統 PICC 因其在提供長期靜脈治療方面的多功能性而廣泛用於臨床環境，同時最大限度地降低與更具侵入性的中心靜脈導管相關的風險。這些設備還配備有利於精確放置、易於維護以及與多種藥物和治療相容的功能。

就最終用途而言，PICC 家庭護理市場市場將在預測期內出現可觀的成長。這是因為強烈需要為患者提供一種方便且具有成本效益的選擇，以便在傳統醫院環境之外接受長期靜脈治療。 PICC 還提供了一種可靠的方法，可將藥物、液體和腸外營養直接注入中心靜脈，從而為需要在家長期治療的慢性病患者提供支持。

到2032 年，亞太地區外周插入中心導管行業規模將大幅成長。營養的管理。亞太地區國家不斷成長的老年人口，加上優先考慮患者舒適度和成本效益的醫療保健政策的轉變，將進一步促進市場擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 傳染病流行率不斷上升
    • 慢性病盛行率上升：
    • 技術進步
    • 醫療保健支出增加以及對 PICC 的偏好增加
  • 產業陷阱與挑戰
    • 導管相關血流感染 (CRBSI) 的高風險
    • 設備故障
• 成長潛力分析
• 監管環境
• 報銷場景
• 技術景觀
• 波特的分析
• PESTEL分析
• 未來市場趨勢

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 電源注入PICC
• 傳統PICC
• 新生兒周邊靜脈導管

第 6 章：市場估計與預測：按 Lumen，2021 - 2032 年

• 主要趨勢
• 單身的
• 雙倍的
• 多種的

第 7 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 化療
• 長期靜脈輸注
• 腸外營養
• 輸血
• 其他應用

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院
• 門診手術中心
• 家庭護理設置
• 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Access Vascular, Inc.
• AngioDynamic, Inc.
• Argon Medical
• B. Braun Medical Ltd
• Becton, Dickinson and Company
• Biowy Corporation
• Cardinal Health, Inc.
• Footprint Medical Incorporated
• ICU Medical, Inc.
• Kimal Plc
• Medi-Tech Devices
• Teleflex Incorporated

Peripherally inserted central catheters market size is set to register 9.6% CAGR during 2024-2032, driven by the rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, which require prolonged administration of medications and fluids. As per WHO, in 2022, approximately 20 million new cancer cases were reported, resulting in 9.7 million mortalities. Peripherally inserted central catheters (PICCs) offer a reliable and less invasive alternative to traditional central venous catheters for providing patients with extended vascular access for weeks to months. This has led to their widespread adoption in hospitals and outpatient settings, where they facilitate the delivery of chemotherapy, parenteral nutrition, and antibiotics, among other therapies.

Innovations, such as antimicrobial coatings and radiopaque materials for accurate placement, and integrated flushing systems are improving infection control, visibility under imaging, and overall catheter management. The shift towards minimally invasive procedures and outpatient care models is also supporting the adoption of PICCs as they offer reduced complication rates and shorter hospital stays compared to traditional central lines.

The peripherally inserted central catheters industry is divided into product, lumen, application, end-use and region.

Based on product, the market size from the conventional PICC segment is poised to generate substantial revenue during 2024-2032 due to its established track record of safety, reliability, and familiarity among healthcare providers. Conventional PICCs are widely used in clinical settings for their versatility in delivering long-term intravenous therapies while minimizing the risks associated with more invasive central venous catheters. These devices are also equipped with features that facilitate precise placement, ease of maintenance, and compatibility with a wide range of medications and treatments.

Concerning end-use, the PICC market from the home-care settings segment is set to witness decent growth over the forecast period. This is backed by the strong need for offering patients a convenient and cost-effective option for receiving long-term intravenous therapy outside of traditional hospital settings. PICCs also provide a reliable method for administering medications, fluids, and parenteral nutrition directly into a central vein, thereby supporting patients with chronic conditions who require prolonged treatment at home.

Asia Pacific peripherally inserted central catheters industry size will surge significantly through 2032. Advancements in healthcare infrastructure and rising healthcare expenditure in the region are supporting the adoption of PICCs in hospitals and outpatient settings, where they facilitate the administration of chemotherapy, antibiotics, and parenteral nutrition. The growing elderly population in APAC countries, coupled with shifting healthcare policies that prioritize patient comfort and cost-efficiency, will further contribute to the market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of infectious diseases
    • 3.2.1.2 Rising prevalence of chronic conditions:
    • 3.2.1.3 Technological advancements
    • 3.2.1.4 Increasing healthcare expenditure and preference for PICCs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High risk of catheter-related bloodstream infections (CRBSI)
    • 3.2.2.2 Malfunctioning of the device
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Power injected PICC
• 5.3 Conventional PICC
• 5.4 Neonatal PICC

Chapter 6 Market Estimates and Forecast, By Lumen, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Single
• 6.3 Double
• 6.4 Multiple

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Chemotherapy
• 7.3 Long-term IV infusion
• 7.4 Parenteral nutrition
• 7.5 Blood transfusion
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory surgical centers
• 8.4 Homecare settings
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Access Vascular, Inc.
• 10.2 AngioDynamic, Inc.
• 10.3 Argon Medical
• 10.4 B. Braun Medical Ltd
• 10.5 Becton, Dickinson and Company
• 10.6 Biowy Corporation
• 10.7 Cardinal Health, Inc.
• 10.8 Footprint Medical Incorporated
• 10.9 ICU Medical, Inc.
• 10.10 Kimal Plc
• 10.11 Medi-Tech Devices
• 10.12 Teleflex Incorporated